Is the marijuana industry on the verge of seeing more legal disputes surrounding patent infringement? One patent lawyer thinks it’s possible.

As the markets see the steady rise of the cannabis business, the possibility of an uptick in courtroom battles over patent use may be appearing soon enough.

In an interview with the Investing News Network (INN), Brian Shortell, a partner with law firm Ballard Spahr, said he is curious to see the development of legal disputes surrounding the enforcement of cannabis-related patents in state and federal courts given the status of the drug in the US.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Despite being legalized across several states for medical or even recreational uses, cannabis remains a scheduled drug at the US federal level. However, this past summer a Denver federal judge made history by allowing a cannabis patent lawsuit to move ahead into a jury trial.

According to a report from Marijuana Business Daily, the suit was filed by United Cannabis against Pure Hemp Collective — both Colorado-based firms — claiming infringement on a “cannabinoid-based medical product formula.”

Shortell told INN he expects to see disputes rise about the legality of enforcing patents for cannabis applications and cannabinoid-related technology.

“They are not finding them invalid based on the subject matter being marijuana,” Shortell said. Given the federal status of the drug, the expectation would have been for the suit to be dismissed.

In terms of the variance in patents related to the marijuana industry, the lawyer has predominantly seen patents connected to formulations, medical treatments and methods of processing.

“It’s basically patents related to taking the active ingredients and being able to use them in other products,” he explained.

Due to the many complications surrounding marijuana reform and policy, Shortell is curious about the impact of a potential winning patent lawsuit regarding cannabis, since the punishment for a court finding patent infringement is that lost profits are awarded.

“Will a court award money damages to a patent holder from the infringer for a substance for sale that is federally illegal?” he questioned.

While patents have different intentions and potential uses, Shortell reminded investors that a patent allows someone to go to court and stop someone from doing something.

“It’s called an exclusionary right or an exclusive right — we can exclude people from that activity or making that product … When one has a patent on a marijuana formulation they can go into court and stop people from making that marijuana formulation,” said Shortell. “The patent holder is doing nothing illegal by having the patent, the patent is to stop an infringer.”

Besides this case in Colorado, the lawyer has not seen any other notable patent-related cases with cannabis involved.

In a previous interview with INN, Dena Jalbert, founder and CEO of Align Business Advisory Services, said she expects to see an increase in the merger and acquisition deal-making space for cannabis based on intellectual property (IP).

“I think most of the deals that we’re going to see are going to be IP specific, because there’s only so much land,” Jalbert said.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!


Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated May 25, 2021 were elected as directors of the Company at Avicanna‘s annual general meeting of shareholders held on June 24, 2021 (the ” Meeting “). The detailed results of the vote for the election of directors held at the Meeting are set out below.

Keep reading... Show less

Quantum 1 Cannabis (CSE:QQ) announced its revenue for the third quarter of 2021 has increased by 672 percent and gross profit has increased by 463 percent compared with the same quarter in 2020. Quantum 1 Cannabis CEO Russ Rossi expounded on this exponential growth and what’s behind this remarkable leap. 

“We had an opportunity during our cannabis training to opt into some leases for cannabis retail. So we thought, let’s take a shot at this and see if we can use our experience with mobile location and supercharge. It paid off. It was a new game for everybody. It’s a lot of luck when opportunity meets preparation,” said Rossi. 

Quantum 1 Cannabis attributed the growth to high month-over-month sales coming from its flagship store in North Vancouver, improved demand for specialized “cottage-grown” sativa and indica products, continued training and hiring of best-of-breed staff and management to cater to consumer inquiries and expanded in-house technology for management of human resources, inventory and regulatory requirements. 

“Our plan is to have the maximum number of retail stores possible in British Columbia. We have 10 year leases on these stores, putting everything in on a solid pitch for the city council. I’m pretty confident that we’re going to have eight centers full blast in BC within six months,” explained Rossi. 

Quantum 1 Cannabis has signed a memorandum of understanding to acquire an approved municipal cannabis retail location in one of Vancouver’s most diverse neighborhoods at 41st Avenue and Cambie Street in Vancouver, British Columbia. The flagship location is expected to expand the company’s footprint in the Lower Mainland.

Watch the full interview with Quantum 1 Cannabis (CSE:QQ) CEO Russ Rossi above.

Keep reading... Show less

Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective and commercially viable

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a process that dramatically increases the production of therapeutics for use in psychedelic-assisted psychotherapy.

Keep reading... Show less

Opening Marks Company’s 107th Retail Location Nationwide

Strategic Expansion Will Help Serve the State’s Rapidly Growing Cannabis Market

Keep reading... Show less

Ayurcann (CSE:AYUR) entered into a joint venture with Bazelet Group, Israel’s largest privately held medical cannabis company. Ayurcann CEO Igal Sudman shared the company’s excitement about bringing unique terpene-enriched medicinal cannabis to the Canadian marketplace. 

“Canada is a very closed-loop country, and the opportunity to bring a variety of different enhancement and technologically advanced products is very important to us. The relationship that we formed with Bazelet is going to enhance our offerings into the Canadian marketplace,” Sudman said. 

Bazelet has launched multiple lines of terpene-enriched cannabis oils; each one is specifically designed for various indications, symptoms and personal needs. The company’s terpene-enriched products are optimized for women’s health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic) and for improved night sleep. 

According to Sudman, there are a lot of larger companies that have tried to do this, but none have been able to successfully bring innovation into the market. Ayurcann is rapidly forging partnerships with several companies worldwide, including Cannmart, Patient Choice and Kindred Partners.

“We’re growing the business, customer base, relationships and partnerships worldwide. We’re bringing the latest technology into Canada, and enhancing not only our company, but the investors’ value moving forward,” added Sudman. 

Watch the full interview with Ayurcann CEO Igal Sudman above.

Keep reading... Show less